On November 10, 2026, BioVie Inc. held its annual meeting of stockholders, marking a significant event for the company and its shareholders. During this meeting, shareholders voted on several key proposals, including the election of directors and amendments to the company's equity incentive plan. The results indicate strong support for the company's leadership and strategic direction.

BioVie Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is publicly traded on the Nasdaq under the ticker symbols BIVI and BIVIW. The company has been actively engaging with its shareholders, as evidenced by the turnout at the annual meeting, where 4,749,367 shares were represented, constituting a quorum.

According to the SEC filing (accession number 0001520138-26-000471), the following proposals were presented and voted on during the meeting:

Proposal 1: Election of Directors

Shareholders elected all nominees for director to hold office until the next annual meeting. The voting results showed significant support for each nominee, with the highest votes for Amy Chappell at 1,732,353 votes in favor.

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

Shareholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2027, with 4,411,653 votes in favor.

Proposal 3: Amendment and Restatement of the 2019 Omnibus Equity Incentive Plan

This proposal to increase the number of shares available for issuance under the plan from 399,509 to 3,100,000 was also approved, with 1,020,704 votes in favor.

The results from these votes indicate a strong alignment between the company's management and its shareholders. The approval of the amendments to the equity incentive plan, in particular, suggests that shareholders are supportive of the company's growth strategies and its approach to incentivizing leadership.

Looking ahead, BioVie Inc. will continue to focus on its strategic initiatives in the pharmaceutical preparations sector. The company's commitment to shareholder engagement and transparency will likely remain a priority as it navigates the evolving landscape of the industry.

Details were not available in the SEC filing regarding any future plans or additional filings following this annual meeting.